IGM Biosciences to Present at Three Upcoming Investor Conferences

IGMS 11.04.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-11
Name of Upcoming Event:Guggenheim Healthcare Innovation Conference
Date of Upcoming Event:2024-11-19
Name of Upcoming Event:Stifel Healthcare Conference
Date of Upcoming Event:2024-11-21
Name of Upcoming Event:Jefferies London Healthcare Conference
Full Press ReleaseSEC FilingsOur IGMS Tweets

About Gravity Analytica

Recent News

  • 01.09.2025 - IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
  • 12.05.2024 - Etzer Darout

Recent Filings

  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.10.2025 - 8-K Current report
  • 01.10.2025 - EX-99.1 EX-99.1
PDF Version

MOUNTAIN VIEW, Calif.,Nov. 04, 2024(GLOBE NEWSWIRE) --IGM Biosciences, Inc.(Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences:

  • Guggenheim Healthcare Innovation ConferenceonMonday, November 11at11:30 a.m. ESTinBoston
  • Stifel Healthcare ConferenceonTuesday, November 19at12:40 p.m. ESTinNew York
  • Jefferies London Healthcare ConferenceonThursday, November 21at8:00 a.m. GMT/3:00 a.m. ESTinLondon

A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website athttps://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentations.

AboutIGM Biosciences, Inc.IGM Biosciencesis a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against immunology and inflammation targets. For more information, please visitwww.igmbio.com.

Contact:Argot PartnersDavid Pitts212-600-1902igmbio@argotpartners.com

Primary Logo

Source: IGM Biosciences, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com